Kalaris Therapeutics (KLRS) Current Assets (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Current Assets of $98.5 million for Q1 2026, down 3.64% year-over-year from $102.2 million in Q1 2025, and down 17.12% quarter-over-quarter from $118.8 million in Q4 2025.
Kalaris Therapeutics (KLRS) Current Assets (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Current Assets history runs 8 years deep, the most recent figure standing at $98.5 million for Q1 2026.
- In Q1 2026, Current Assets fell 3.64% year-over-year to $98.5 million; the TTM figure through Mar 2026 stood at $98.5 million (down 3.64% YoY), while the FY2025 annual figure was $118.8 million, up 4459.06% from the prior year.
- Current Assets for Q1 2026 stood at $98.5 million, down from $118.8 million in the prior quarter.
- The five-year high for Current Assets was $272.0 million in Q3 2022, with the low at $2.6 million in Q4 2024.
- The 5-year median for Current Assets is $141.5 million (2024), against an average of $156.3 million.
- The sharpest annual moves came in 2024 and 2025: Current Assets plunged 98.61% in 2024, then surged 4459.06% in 2025.
- Kalaris Therapeutics' Current Assets stood at $243.1 million in 2022, then decreased by 22.8% to $187.6 million in 2023, then slumped by 98.61% to $2.6 million in 2024, then soared by 4459.06% to $118.8 million in 2025, then fell by 17.12% to $98.5 million in 2026.
- Business Quant data shows KLRS's Current Assets at $98.5 million in Q1 2026, $118.8 million in Q4 2025, and $78.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | Kalaris Therapeutics | 97.57 Mn | 97.57 Mn | - | 95.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.92 Mn |
| Mar 31, 2026 | 98.47 Mn |
| Dec 31, 2025 | 118.81 Mn |
| Sep 30, 2025 | 78.18 Mn |
| Jun 30, 2025 | 91.65 Mn |
| Mar 31, 2025 | 102.18 Mn |
| Dec 31, 2024 | 2.61 Mn |
| Sep 30, 2024 | 122.53 Mn |
| Jun 30, 2024 | 129.94 Mn |
| Mar 31, 2024 | 141.48 Mn |
| Dec 31, 2023 | 187.64 Mn |
| Sep 30, 2023 | 220.02 Mn |
| Jun 30, 2023 | 252.91 Mn |
| Mar 31, 2023 | 212.28 Mn |
| Dec 31, 2022 | 243.05 Mn |
| Sep 30, 2022 | 272.04 Mn |
| Jun 30, 2022 | 176.52 Mn |
| Mar 31, 2022 | 206.44 Mn |
| Dec 31, 2021 | 253.35 Mn |
| Sep 30, 2021 | 281.87 Mn |